Kowa Submits NCX 470 NDA to FDA, Triggering €3 Million Milestone Payment to Nicox

A standard 12-month FDA review clock is now running on NCX 470 (bimatoprost grenod), after Nicox SA's exclusive U.S. licensee, Kowa Company, Ltd., filed the New Drug Application on July 1, 2026, setting a mid-2027 approval target and triggering a €3 million milestone payment to Nicox, with a further payment contingent on approval.

The NDA rests on data from two Phase 3 trials, Mont Blanc and Denali, designed jointly to satisfy regulatory requirements in both the United States and China. Both studies demonstrated clinically meaningful intraocular pressure reductions with a favorable safety profile in patients with open-angle glaucoma or ocular hypertension. The dual-market trial design reflects a deliberate regulatory efficiency: a single clinical dataset supporting parallel NDA and Chinese submission pathways under Nicox's split-licensing structure.

For regulatory affairs leads tracking out-licensing models, the Nicox-Kowa arrangement is a functional case study. Nicox retains milestone economics and scientific oversight while Kowa carries the regulatory submission burden, including FDA correspondence, labeling negotiations, and the review-period workload. Ocumension Therapeutics holds the equivalent license for China, South Korea, and Southeast Asia; Kowa covers Japan and the rest of the world. The structure distributes regulatory execution risk across licensees while concentrating scientific IP at the originator.

Kowa's Director and Senior Managing Executive Officer Junichi Kawagoe indicated that commercial launch preparation is already underway, with U.S. launch planned shortly after a mid-2027 approval. That timeline compresses the window between NDA acceptance, any potential Complete Response Letter risk, and commercial readiness, a sequencing that supply chain and manufacturing teams at both organizations will need to track against standard FDA review milestones.

NCX 470 is a nitric oxide-donating bimatoprost eye drop, a mechanism class that adds a secondary IOP-lowering pathway to an established prostaglandin analogue scaffold. Whether that differentiation supports a distinct label claim will depend on FDA's review of the Mont Blanc and Denali datasets against the existing bimatoprost reference standard.

If the review proceeds on the standard 12-month track without a major amendment request, the approval decision would land in mid-2027, with commercial launch targeted before year-end 2027.

Source: Nicox SA via GlobeNewswire, July 1, 2026.